Up 2.2x in three days, HLB Biostep has filed nothing

Seoul — The KOSPI fell 2.62% to 6,625.93 and the KOSDAQ (tech- and small-cap-heavy market) lost 0.69% to 892.27 on Oct. 8, but KOSDAQ-listed HLB Biostep (278650, +29.97%) and Samki Energy Solutions (419050, +29.93%) and KOSPI-listed HLB Global (003580, +29.8%) rose close to the 30% daily limit. None of the three has a filing on DART (Korea's official disclosure system) that explains the move; the reasons come only from news reports. For the two HLB companies it is drug hopes spreading through the HLB group, and for Samki Energy Solutions it is brokerage-style research and ESS expectations.

HLB Biostep: third straight day near the limit, with no company filing

HLB Biostep rose because it was reported as part of an HLB group rally on hopes for the group's drug, and DART shows no filing in the past seven days. Edaily ran a headline saying HLB affiliates hit the limit on "ribosertib hopes," and CBC News and Economy Today reported the rise and the group-stock pattern. The headlines do not explain how this company connects to ribosertib. Korea Technology Finance Corp. described it in a Sept. 26, 2025 report as a one-stop preclinical CRO (contract research) company covering preclinical and toxicity testing. Moving in sympathy with the group may be the explanation, though that is an inference.

After gains of about 30% on each of Oct. 6, 7 and 8, the stock went from 2,885 won on Oct. 2 to 6,310 won, roughly 2.2 times. It is up 159.1% from Sept. 1. Market cap is 110.0 billion won and trading value was 32.9 billion won, about 30% of market cap in a day. It was already up 29.97% at 1:30 p.m., unchanged at the close. On Oct. 7, individuals net bought 31,518 shares while foreigners net sold 29,075.

Two things will show whether this lasts: whether the company itself discloses anything on DART tied to the HLB drug, and whether trading value stays in the 30 billion won range tomorrow.

Samki Energy Solutions: up 29.93% on the day ESS research landed

Samki Energy Solutions rose on a morning wave of research and articles calling energy storage systems (ESS) its new growth axis. According to Newsis, Smallinsight Research said on Oct. 8 that FF-PCBs (flat flexible printed circuit boards) for ESS and the North American business are emerging as growth drivers. Etoday headlined a shift from EV parts to ESS and AI, and Money Today wrote about AI data center ESS as a growth engine. Wide Economy ran a headline saying component sales tripled, but the company has not confirmed that figure in a filing. DART shows no filing in the past seven days.

The close of 2,305 won is up 26.6% over two days. The stock also rose 17.53% on Sept. 23 before drifting back to the 1,700-1,800 won range. Trading value was 53.9 billion won, about 41% of its 131.8 billion won market cap. On Oct. 6, foreigners net sold 49,483 shares while individuals bought the same amount; flows for the day of the rise are not yet out.

What matters is whether the ESS sales the research points to appear in quarterly results or disclosed orders. For now articles and analyst commentary are the whole basis, so this is expectation. The move was the same at 1:30 p.m. as at the close.

HLB Global: carried up with the HLB group on drug hopes

HLB Global was reported to have risen alongside the HLB group on drug hopes. Business Post wrote that HLB group stocks were strong on expectations for a bile-duct cancer drug, and iNews24 reported on Oct. 7 that HLB's move to refile with the U.S. FDA for liver-cancer drug ribosertib had spread investor sentiment across the group. The same piece suggested sorting out which affiliates really connect to the drug. The one DART filing in the past seven days is a Oct. 1 large-holding report (short form) from Synergy IB Investment; its relation to the rise is not established.

The close of 2,635 won is up 27.3% over two days and 33.8% over five. It also rose 16.88% on Oct. 6, when foreigners net sold 200,840 shares and individuals net bought 217,236. Trading value was 12.9 billion won, about 10% of its 133.5 billion won market cap. Job Post wrote on Oct. 6 that diversifying its business and narrowing its losses are the company's challenges.

Watch whether the group's drug schedule reaches this company's revenue or earnings, or whether it falls back with the group once the hopes cool. It also came near the limit on Sept. 28 (29.82%), so selling by recent buyers is another thing to watch.

How the stocks we covered earlier have done

The six stocks we labeled "reports only" earlier closed Oct. 8 at: Sandslab -15.9%, Winpac -8.2%, Mercury -4.6%, TMC -2.3%, RaonSecure +3.0%, HLB Pharmaceutical +0.4% versus the earlier articles. Four of six are lower, with an average of -4.6%. Brils, covered on its listing day, fell 32.1% from 34,100 won to 23,150 won. LK Samyang, where no reason was found, rose 2.1% from 4,260 won to 4,350 won.